RA
CLVS

Royce & Associates’s Clovis Oncology, Inc. CLVS Stock Holding History

Royce & Associates’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-50,000
Closed -$3.4M – 1294
2017
Q4 		$3.4M Hold
50,000
– – 0.02% 706
2017
Q3 		$4.12M Sell
50,000
-16,000
-24% -$1.27M 0.03% 635
2017
Q2 		$6.18M Sell
66,000
-10,000
-13% -$612K 0.04% 524
2017
Q1 		$4.84M Hold
76,000
– – 0.03% 585
2016
Q4 		$3.38M Buy
+76,000
New +$2.67M 0.02% 683

Other funds holding CLVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $7.71B AUM 4.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Royce & Associates's CLVS Position: Q1 2018 in Review

Royce & Associates sold out of Clovis Oncology, Inc. (CLVS) in Q1 2018, closing a stake of 50,000 shares — an estimated $3.4M sold.

Royce & Associates first reported a position in CLVS in Q4 2016 and held it in 5 quarters. The position peaked at $6.18M in Q2 2017. 229 funds tracked by Wall St. Rank hold CLVS as of Q1 2018.

  • Royce & Associates reported no remaining Clovis Oncology, Inc. position as of Q1 2018 after selling out during the quarter.
  • Royce & Associates sold 50,000 Clovis Oncology, Inc. shares in Q1 2018, an estimated $3.4M.
  • Royce & Associates first reported a position in Clovis Oncology, Inc. in Q4 2016 and held it in 5 quarters.
  • Royce & Associates's Clovis Oncology, Inc. position peaked at $6.18M in Q2 2017.
  • 229 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2018.

Based on Royce & Associates's 13F filing for Q1 2018, filed 14 May 2018.